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Abstract: Clostridium perfringens β-toxin (CPB) is the major virulence factor of C. perfringens type C
causing a hemorrhagic enteritis in animals and humans. In experimentally infected pigs, endothelial
binding of CPB was shown to be associated with early vascular lesions and hemorrhage but without
obvious thrombosis of affected vessels, suggesting altered hemostasis in the early phase of the disease.
The objective of the present study was to investigate the effect of CPB on platelets, with respect
to primary hemostasis. Our results demonstrate that CPB binds to porcine and human platelets
and forms oligomers resulting in a time- and dose-dependent cell death. Platelets showed rapid
ultrastructural changes, significantly decreased aggregation and could no longer be activated by
thrombin. This indicates that CPB affects the physiological function of platelets and counteracts
primary hemostasis. Our results add platelets to the list of target cells of CPB and extend the current
hypothesis of its role in the pathogenesis of C. perfringens type C enteritis.
Keywords: Clostridium perfringens type C; beta-toxin; platelets
1. Introduction
Clostridium perfringens β-toxin (CPB) is a soluble 35 kD protein and belongs to the haemolysin
family of β-pore forming toxins (β-PFTs) [1,2]. It is the major virulence factor of C. perfringens type C [3],
which causes an acute necro-hemorrhagic enteritis in animals and humans. CPB forms oligomeric pores
in different neoplastic human immune cell lines [4–6] and endothelial cells [7,8]. CPB is highly toxic to
porcine and human endothelial cells [9,10] and induces a disruption of the cytoskeleton, the retraction
of the cell borders, and necrotic cell death [8]. As opposed to endothelial cells, porcine small intestinal
epithelial cells are unaffected by CPB, even at high concentrations [11]. Physiologically, endothelial
injury initiates primary hemostasis by exposing platelets to subendothelial matrix, including von
Willebrand factor (vWF) and collagen, which leads to binding and activation of platelets. Activated
platelets undergo rapid morphological changes and release pro-thrombotic and pro-inflammatory
mediators from their granules, which promotes the recruitment of further platelets, adhesion and
primary hemostasis [12–14]. In end-stage lesions of spontaneously diseased pigs, CPB can consistently
be demonstrated on endothelial cells of thrombosed intestinal mucosal vessels [15]. Interestingly,
in experimentally induced lesions in piglets, Schumacher et al. [16] observed endothelial binding of
CPB, which was associated with early vascular lesions such as edema and extravasation of erythrocytes
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but without obvious thrombosis of affected vessels. Thus, despite early endothelial targeting by CPB,
thrombus formation seems to be a late event in the disease and the progressive hemorrhage might be
favored by simultaneous anti-thrombotic effects. We hypothesized that besides endothelial cells, CPB
also targets platelets and that a direct toxic effect on these blood components could contribute to the
progressive tissue hemorrhage observed in C. perfringens type C enteritis. The objective of this study,
therefore, was to investigate the effect of CPB on porcine and human platelets.
2. Results
2.1. Cytotoxicity of rCPB and Morphological Effects of rCPB on Platelets
Incubation of porcine and human platelets with recombinant CPB (rCPB) resulted in a time and
dose-dependent reduction of platelet viability (Figures 1 and 2). Platelets showed a rapid loss of
Calcein-AM fluorescence when incubated with 250 ng/mL rCPB. A marked effect was already detected
at 15 min of incubation and the majority of platelets had lost Calcein-AM fluorescence after 30 min of
toxin incubation. Cytotoxic effects in porcine and human platelets were detectable at very low toxin
concentrations of 10 ng/mL (porcine, Figure 1) or 50 ng/mL (human, Figure 2) rCPB. Control incubations
with neutralized rCPB or DMEM (Dulbecco's Modified Eagle's Medium) did not affect the viability
of platelets.
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Figure 1. Detection of recombinant Clostridium perfringens β-toxin (rCPB)-induced rapid cell death in 
porcine platelets by flow cytometry. Platelets (33.3 × 106/mL) were incubated with rCPB (10 and 250 
ng/mL) or neutralized rCPB for indicated time periods. Viability staining was performed using 
Calcein-AM (1 μM). Platelets in medium without toxin served as negative control. The histograms 
show the Calcein-AM fluorescence intensity of platelets, in which the Calcein-AM positive fraction 
represents viable platelets. Percentages of platelets are indicated in the top of each panel. 
Figure 1. Det ction of reco i l stridium pe fringens β-toxin (rCPB)-induced rapid c ll death
in porcine plat lets by flow cytometry. Platelets (33.3 × 106/mL) were ncubated with rCPB
(10 and 250 ng/mL) or neutralized rCPB for indicated time periods. Vi bility st ining was performed
using Calcein-AM (1 µM). Platelets in medium without toxin served as negative control. The histograms
show the Calcein-AM fluorescence intensit f l t l ts, i ich the Calcein-AM positive fraction
represents viable platelets. Percentages of platelets are indicated in the top of each panel.
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Figure 2. Detection of rCPB-induced cell death in human platelets by flow cytometry. Platelets (33.3 
× 106/mL) were incubated with rCBP (50 and 250 ng/mL) or neutralized rCPB for indicated time 
periods. The viability staining was performed using Calcein-AM (1 μM). Platelets in medium only 
without toxin served as negative control. Percentages of positively and negatively labeled platelets 
are indicated in the top of each panel. 
In addition, porcine and human platelets showed early morphological changes when incubated 
with rCPB (Figures 3 and 4). After 5 min of incubation with 250 ng/mL rCPB, a loss of the discoid 
platelet shape and formation of small pseudopodia was visible. After 15 min, porcine platelets 
showed rounding, while human platelets appeared swollen with pseudopodia entwining the platelet 
body. After 60 min of incubation, porcine and human platelets appeared shrunken and rounded with 
loss of pseudopodia compared to controls.  
Platelets incubated with neutralized rCPB or PBS (Figures 3 and 4) showed formation of small 
pseudopodia but no signs of modification of the pseudopodia or the platelet shape over time.  
Figure 2. Detection of rCPB-induced cell death in human platelets by flow cytometry. Platelets
(33.3 × 106/mL) were incubated with rCBP (50 and 250 ng/mL) or neutralized rCPB for indicated time
periods. The viability staining was performed using Calcein-AM (1 µ ). Platelets in medium only
without toxin served as negative control. Percentages of positively and negatively labeled platelets are
indicated in the top of each panel.
In addition, porcine and human platelets showed early morphological changes when incubated
with rCPB (Figures 3 and 4). After 5 min of incubation with 250 ng/mL rCPB, a loss of the discoid
platelet shape and formation of small pseudopodia was visible. After 15 min, porcine platelets showed
rounding, while human platelets appeared swollen with pseudopodia entwining the platelet body.
After 60 min of incubation, porcine and human platelets appeared shrunken and rounded with loss of
pseudopodia compared to controls.
Platelets incubated with neutralized rCPB or PBS (Figures 3 and 4) showed formation of small
pseudopodia but no signs of modification of the pseudopodia or the platelet shape over time.
Toxins 2017, 9, 336 4 of 15
Toxins 2017, 9, 336  4 of 15 
 
 
Figure 3. Analysis of the morphological effect of rCPB on porcine platelets using scanning electron 
microscopy. Platelets exposed to rCPB (250 ng/mL) showed rapid morphological changes compared 
to PBS-incubated platelets. Morphological effects were inhibited by antibody-mediated neutralization 
of rCPB. Scale bars: 5 μm (5.000×) or 1 μm (30.000×). 
Figure 3. Analysis of the morphological effect of rCPB on porcine platelets using scanning electron
microscopy. Platelets exposed to rCPB (250 ng/mL) showed rapid morphological changes compared to
PBS-incubated platelets. Morphological effects were inhibited by antibody-mediated neutralization of
rCPB. Scale bars: 5 µm (5.000×) or 1 µm (30.000×).
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Figure 4. Morphological effect of rCPB on human platelets. Platelets exposed to rCPB (250 ng/mL) 
showed rapid morphological changes compared to PBS-incubated platelets. The morphological effect 
was inhibited by antibody-mediated neutralization of rCPB. Scale bars: 5 μm (5.000×) or 1 μm (30.000×). 
2.2. Platelet Binding and Oligomerization of rCPB 
To demonstrate the binding of rCPB on platelets, scanning electron microscopy (SEM) combined 
with immunogold labeling of rCPB was performed. Toxin (250 ng/mL)-treated platelets showed a 
signal of back-scattered electrons (BSE) of rCPB after 5 min of incubation and this signal increased at 
longer incubation times (Figures 5 and 6). Controls, incubated with neutralized rCPB or PBS, 
remained unlabelled. 
Figure 4. orphological effect of rCPB on hu an platelets. Platelets exposed to rCPB (250 ng/ L)
sho ed rapid morphological changes compared to PBS-incubated platelets. The morphological
effect was inhibited by antibody-mediated neutralization of rCPB. Scale bars: 5 µm (5.000×) or
1 µm (30.000×).
2.2. Platelet Binding and Oligomerization of rCPB
To demonstrate the binding of rCPB on platelets, scanning electron microscopy (SEM) combined
with immunogold labeling of rCPB was performed. Toxin (250 ng/mL)-treated platelets showed a
signal of back-scattered electrons (BSE) of rCPB after 5 min of incubation and this signal increased
at longer incubation times (Figures 5 and 6). Controls, incubated with neutralized rCPB or PBS,
remained unlabelled.
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Figure 5. SEM backscattered electron image of rCPB bound on porcine platelets. Platelets were 
incubated with PBS, neutralized rCPB or rCPB (250 ng/mL) for indicated time points. Arrows indicate 
immuno-gold labeled rCPB. Scale bars: 1 μm, 30.000× magnification. 
 
Figure 6. SEM backscattered electron image of rCPB bound on human platelets. Human platelets were 
incubated with PBS, neutralized rCPB or rCPB (250 ng/mL) for indicated time points. Arrows indicate 
immuno-gold labeled rCPB. Scale bars: 1 μm, 30.000× magnification. 
Figure 5. SEM backscattered electron image of rCPB bound on porcine platelets. Platelets were
incubated with PBS, neutralized rCPB or rCPB (250 ng/mL) for indicated time points. Arrows indicate
immuno-gold labeled rCPB. Scale bars: 1 µm, 30.000× magnification.
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Figure 6. SEM backscattered electron image of rCPB bound on human platelets. Human platelets were
incubated with PBS, neutralized rCPB or rCPB (250 ng/mL) for indicated time points. Arrows indicate
immuno-gold labeled rCPB. Scale bars: 1 µm, 30.000× magnification.
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Western blotting of RIPA(Radioimmunoprecipitation assay buffer) lysates of porcine and human
platelets incubated with rCPB depicted, in addition to the 35 kDa monomeric form, that a prominent
Western blot signal appeared at appr. 230 kDa (Figure 7), which corresponds to previously published
CPB oligomers and an expected size of heptameric toxin complexes at the plasma membrane [4].
In addition, several high molecular weight bands between 220 kDa and appr. 130 kDa were present.
The high molecular weight forms were demonstrated after 5 min of incubation of platelets with rCPB
and the intensity of the band increased over time.
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stimulation. Control incubations with neutralized rCPB or DMEM showed weak positive signals with 
a maximum of appr. 12% positive platelets, whereas incubation with neutralized rCPB resulted in 
slightly higher percentages of positive platelets after 5 and 15 min of incubation. The signal of porcine 
and human platelets exposed to rCPB was slightly higher compared to negative controls but 
considerably weaker compared to thrombin activation. 
Figure 7. Binding and oligomerization of rCPB on porcine and human platelets. Porcine (A) and
human (B) platelets were incubated with 1 µg/mL rCPB for indicated time periods, washed with PBS,
lysed in RIPA buffer and boiled in SDS (Sodium Dodecyl Sulfate) loading buffer followed by SDS
PAGE (Polyacrylamid Gel Electrophoresis) and Western blotting. A major band representing CPB
oligomers located at a molecular mass of appr. 230 kDa. The monomeric form of CPB localizes at
35 kDa. Controls show purified monomeric rCPB and porcine and human platelet lysates without
toxin incubation (0 min). Western blots were developed using monoclonal anti CPB and secondary
antibody IRDye 680 CW.
2.3. Lack of Marked Platelet Activation by rCPB
As a marker for platelet activation, we investigated translocation of the platelet
activation-dependent granule- external membrane protein CD62P to the plasma membrane by flow
cytometry (Figure 8). Porcine and human platelets were incubated with rCBP (250 ng/mL), neutralized
rCPB or DMEM for indicated time points. Incubation of porcine and human platelets with thrombin
(2.5 U) served as a positive control and resulted in a >90% positive signal after 5 min and 15 min
of stimulation. Control incubations with neutralized rCPB or DMEM showed weak positive signals
with a maximum of appr. 12% positive platelets, whereas incubation with neutralized rCPB resulted
in slightly higher percentages of positive platelets after 5 and 15 min of incubation. The signal of
porcine and human platelets exposed to rCPB was slightly higher compared to negative controls but
considerably weaker compared to thrombin activation.
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Figure 8. rCPB does not induce marked activation of porcine (A) and human (B) platelets. Platelets 
(33.3 × 106/mL) were incubated with rCBP (250 ng/mL), thrombin (2.5 U), neutralized rCPB or DMEM 
for indicated time points. CD62P-PE labeled antibody was used as activation marker. The histograms 
show the Phycoerythrin (PE)-fluorescence intensity of porcine and human platelets, in which the PE 
positive fraction represents activated platelets.  
2.4. Effect of rCPB on Platelet Function 
To assess whether CPB toxicity on platelets results in a loss of function, we performed a 
functional platelet aggregation assay established for human blood samples. This assay is performed 
with a platelet function analyser which aspirates whole blood into a test cartride through a small 
aperture of a membrane. The membrane is coated with collagen and adenosin diphosphat (ADP) and 
thus activates platelets to form a plug which closes the aperture. Addition of rCPB (1 μg/mL) to 
human blood samples followed by different incubation periods (15 min, 30 min or 60 min) led to a 
markedly prolonged aperture closure time of >140 s at 15 min and 30 min (Figure 9). At 60 min, no 
closure was achieved within the measurement interval of the test system, indicating failure of 
platelets to aggregate. Control samples were left untreated or incubated either with neutralized rCPB 
or the 10A2 antibody only. Closure times of all controls remained within the physiological range of 
Figure 8. rCPB does not induce marked activation of porcine (A) and human (B) platelets. Platelets
(33.3× 106/mL) were incubated with rCBP (250 ng/mL), thrombin (2.5 U), neutralized rCPB or DMEM
for indicated time points. CD62P-PE labeled antibody was used as activation marker. The histograms
show the Phycoerythrin (PE)-fluorescence intensity of porcine and human platelets, in which the PE
positive fraction represents activated platelets.
2.4. Effect of rCPB on Platelet Function
To assess whether CPB toxicity on platelets results in a loss of function, we performed a functional
platelet aggregation assay established for human blood samples. This assay is performed with a
platelet function analyser which aspirates whole blood into a test cartride through a small aperture
of a membrane. The membrane is coated with collagen and adenosin diphosphat (ADP) and thus
activates platelets to form a plug which closes the aperture. Addition of rCPB (1 µg/mL) to human
blood samples followed by different incubation periods (15 min, 30 min or 60 min) led to a markedly
prolonged aperture closure time of >140 s at 15 min and 30 min (Figure 9). At 60 min, no closure
was achieved within the measurement interval of the test system, indicating failure of platelets to
aggregate. Control samples were left untreated or incubated either with neutralized rCPB or the
Toxins 2017, 9, 336 9 of 15
10A2 antibody only. Closure times of all controls remained within the physiological range of >65 s
to <130 s. The differences between the controls and rCPB-incubated groups were highly significant
(ANOVA p-value < 0.05). The multiple comparisons Bonferronni-corrected tests showed that groups
of controls (untreated blood, incubation with neutralized rCPB or antibody only) differed from the
groups which were incubated with rCPB (15 min, 30 min and 60 min (Figure 9)).
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was highly extended at 60 min (p < 0.001).  
In addition to this functional test, we evaluated whether platelets could still be activated after 
exposure to rCPB using electron microscopy. Addition of the platelet activator thrombin (2.5 U/mL) 
to PBS-treated platelets resulted in platelet activation with typical shape changes and formation of 
multiple pronounced pseudopodia. In contrast, toxin-treated platelets showed no morphological 
signs of activation by thrombin, even after 5 min of exposure to 250 ng/mL rCPB (Figures 10 and 11). 
Figure 9. Exposure of whole human blood to rCPB nhibits p a elet aggregation. Whole blood
was incubated with rCBP (1 µg/mL) for in icated time points. Untreate blood or incubat on
with neutralized rCPB or monoc onal antibody 10A2 served as controls. ANOVA, T key– ra er
ultiple-Comparison Test. Asterisks describe the evel of s gnificance: * p < 0.05, ** p < 0.01,
*** p < 0.001.
The box plot shows the closure time of the aperture by platelet plug formation. Asterisks indicate
significant differences between groups. Whole blood incubated with rCPB for 15 min showed a
significant prolonged closure time (p < 0.05) compared to untreated whole blood. The closure time was
highly extended at 60 min (p < 0.001).
In addition to this functional test, we evaluated whether platelets could still be activated after
exposure to rCPB using electron microscopy. Addition of the platelet activator thrombin (2.5 U/mL)
to PBS-treated platelets resulted in platelet activation with typical shape changes and formation of
multiple pronounced pseudopodia. In contrast, toxin-treated platelets showed no morphological signs
of activation by thrombin, even after 5 min of exposure to 250 ng/mL rCPB (Figures 10 and 11).
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Figure 11. Human platelets exposed to rCPB are irresponsive to thro bin activation. Platelets were
incubated with PBS or rCPB for the indicated times follo ed by addition of thrombin. While control
platelets reacted to thrombin with typical shape change and formation of pseudopodia at all time
points, platelets incubated with rCPB (250 ng/mL) showed only slight signs of activation at 5 min and
did not display thrombin-induced changes after 15 or 60 min of toxin exposure.
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3. Discussion
Our results demonstrate that CPB is highly toxic to porcine and human platelets. The cytopathic
effect induced by CPB occurs very rapidly leading to morphological changes of platelets within a
few minutes of exposure to the toxin. Furthermore, we demonstrated that CPB binds to porcine and
human platelets and forms oligomers. Using scanning immune-electron microscopy, we confirmed
the binding of CPB at the plasma membrane of porcine and human platelets. Affected platelets did
not exhibit marked signs of primary activation, showed markedly reduced ability to aggregate and
could not be activated by thrombin, indicating that CPB counteracts the physiological function of
porcine and human platelets by inducing rapid cell death. We therefore propose that, in addition to
endothelial cells, CPB targets platelets in vivo and has an inhibitory effect on primary hemostasis.
This may explain the discrepancy between our previous observations in naturally infected piglets [15],
a human case of Enteritis Necroticans [17] and an experimental infection model in newborn piglets [16].
Whereas thrombosis of mucosal vessels is a typical feature of end-stage lesions in naturally infected
piglets, early histological lesions in an ileal loop model in newborn piglets were characterized by
vascular leakage and hemorrhage without visible signs of early hemostasis by platelet aggregation and
thrombus formation. Endothelial cell damage, as shown to be induced by CPB [9,10], would expose the
subendothelial extracellular matrix during natural disease. This, in turn, would activate the hemostatic
process [12,18,19] with adherence of platelets to vWF and collagen leading to platelet activation.
Once activated, platelets change shape and release platelet agonists from their pre-formed granules
(alpha and delta granules). These pro-thrombotic and pro-inflammatory mediators recruit and activate
further platelets, leading to clot stabilization, retraction and thrombus formation. The targeting of
platelets by CPB, as shown by our in vitro results, would lead to an impairment of primary hemostasis
in vivo and could in part explain the massive and protracted intestinal hemorrhage observed in
C. perfringens type C-induced enteritis [16]. Therefore, CPB may not only be responsible for early
endothelial damage but also contribute to prolonged bleeding from damaged vessels. With regard
to host–pathogen interaction, this would make sense, as it provides the bacterium with optimal
growth conditions enabling C. perfringens to proliferate rapidly and even upregulate secretion of
CPB and other toxins [20,21]. Once initiated, this would lead to a vicious cycle culminating in the
segmental hemorrhagic necrosis of the small intestinal wall. A major role of CPB in the pathogenesis
of C. perfringens type C enteritis therefore is the induction of hemorrhage during the early phases of
the disease process.
Our results indicate that porcine platelets were slightly more susceptible to rCPB than human
platelets, despite the fact that oligomers formed in both platelet types. This difference has not been
detected so far in human and porcine endothelial cells [9,10]. Possible reasons are species-specific
characteristics of platelets. It is well known that differences in receptor expression exist together
with differences in granule content [22–24]. Composition and quantity of coagulation factors are also
influenced by the species, which plays an important role in the hemostatic process [22,25]. In-depth
studies of the membrane interactions of CPB with porcine and human target cells would be required
to investigate this difference. Nevertheless, human platelets were still highly susceptible to CPB and
showed very similar reaction patterns as porcine platelets. In conclusion, our results add platelets
to the list of target cells for CPB and extend the current hypothesis of the role of this toxin in the
pathogenesis of C. perfringens type C enteritis.
4. Materials and Methods
4.1. Isolation of Platelets
Pig blood was collected at the Institute of Virology and Immunology, Mittelhäusern, Switzerland,
and was approved by the cantonal veterinary office. Porcine platelets were isolated from citrated blood
of specific pathogen-free pigs using different centrifugation steps (1st: 1.000 g, 20 min, 4 ◦C; 2nd: 2.500 g,
10 min, 4 ◦C). Human platelets were obtained from apheresis filters from the Blood Transfusion Center,
Toxins 2017, 9, 336 12 of 15
Bern (project nr. 129). Donor blood was tested according to the Swiss regulations for the preparation
of blood and blood components (Heilmittelgesetz, HMG). The study was conducted in accordance
with the Declaration of Helsinki. All subjects gave their informed consent for inclusion of anonymized
biological material derived from their blood samples in research studies. Due to anonymization of
all blood samples, our study was not regulated by the Swiss Human Research Law (HFG). Human
platelets were isolated by centrifugation (1st: 600 g, 20 min, 4 ◦C; 2nd: 2.500 g, 10 min, 4 ◦C). Platelets
were counted using the MUSE Cell Analyzer (Merck Millipore, Merck KGaA, Darmstadt, Germany),
diluted as required for the subsequent experiments and stored at 4 ◦C in Dulbecco’s Modified Eagle
Medium (DMEM, Gibco, Paisley, UK) containing 10% fetal calf serum (FCS) or in Dulbecco’s Phosphate
Buffered Saline (PBS, Gibco, Paisley, UK) until further processing.
4.2. Incubation of Platelets with Recombinant Clostridium Perfringens β-Toxin
Recombinant CPB (rCPB) was produced as previously described [10]. Thrombin, which was
used for rCPB production, was removed using streptavidin-coated beads. Platelets were incubated
with rCPB at 37 ◦C. As negative controls, platelets were incubated in DMEM or PBS without addition
of toxin or rCPB was neutralized with anti CPB monoclonal antibody 10A2 (100 µL/mL, Center for
Veterinary Biologics, Ames, IA, USA) for 30 min at room temperature (RT). Incubation of platelets with
2.5 U thrombin (Sigma-Aldrich, Buchs, Switzerland) was used as a control for activated platelets.
4.3. Flow Cytometry
Isolated porcine and human platelets were transferred to 5 mL FACS (fluorescence-activated cell
sorting) tubes at 5 × 106 platelets per tube and incubated with 10 and 250 ng/mL (porcine) or 50 and
250 ng/mL (human) rCPB, neutralized rCPB or DMEM (15, 30, 60 and 120 min). After incubation,
platelets were washed with PBS and centrifuged at 700× g for 5 min at 4 ◦C. For viability staining
platelets were resuspended in PBS, stained with Calcein-AM (1 µM; Sigma-Aldrich Chemie GmbH,
Buchs, Switzerland) for 30 min at 37 ◦C and analyzed using a BD FACS Canto II flow cytometer
(BD Biosciences, Allschwil, Switzerland). Data were analyzed using FlowJo software 8 (Tree Star Inc.,
Ashland, OR, USA). For the determination of platelet activation, porcine and human platelets
were incubated with rCPB (250 ng/mL) or thrombin (2.5 U, Sigma-Aldrich, Buchs, Switzerland).
After incubation (15 and 30 min) platelets were washed with PBS and centrifuged at 700× g for 5 min at
4 ◦C to remove unbound rCPB. Labelling was performed with anti-CD62 antibodies (clone Psel.KO.2.5,
Bio-Rad, USA or clone AK4, Lubio Science GmbH, Zurich, Switzerland) for 30 min on ice followed by
washing with PBS, centrifugation and analyzation with BD FACS as described above.
4.4. Scanning Electron Microscopy
Porcine and human platelets (1 × 109/mL) were incubated with rCPB (250 ng/mL), neutralized
rCPB or PBS for 5, 15 and 60 min. Thereafter, 2.5U of thrombin were added to samples immediately
after incubation for 1 min. After washing with PBS and centrifugation at 700× g for 5 min,
samples were fixed with 2.5% glutaraldehyde (Merck, Darmstadt, Germany) in 0.1 M cacodylate
buffer, pH 7.2, for 45 min at RT. Fixed samples were centrifuged at 125× g for 5 min in a cytospin
centrifuge (Hettich Universal 320, Tuttlingen, Germany) onto gold-sputtered and Poly-L-Lysin-coated
(Sigma P8920, 0.1%) coverslips. Postfixation was done with 2% OsO4 (Polysciences, Warrington,
PA, USA) in 0.1 M cacodylate buffer for 30 min. After two washes in 0.1 M cacodylate buffer,
the samples were dehydrated through an ascending ethanol series and dried by evaporation of
Hexamethyldisilazane (Merck, Schaffhausen, Switzerland) as described previously [26,27]. Afterwards,
the coverslips were mounted on metal stubs with conductive adhesive tabs (Ted Pella, Redding,
CA, USA) and sputter-coated with approximately 20 nm of gold with an SCD004 (BalTec, Balzers,
Liechtenstein). Secondary electron micrographs were obtained with a field emission scanning electron
microscope DSM 982 Gemini (Zeiss, Oberkochen, Germany) at an accelerating voltage of 5 kV at
a working distance of 5–8 mm and a magnification of 30.000×. Binding of rCPB to platelets was
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investigated by immuno-scanning electron microscopy. Porcine and human platelets (1 × 109/mL)
were incubated with rCPB (250 ng/mL), neutralized rCPB or PBS for 5, 15 and 60 min at RT. After
washing with PBS and centrifugation at 700× g for 5 min, samples were fixed with 4% buffered
formaldehyde (Methanol-free, Thermo Scientific, Waltham, MA, USA) for 30 min at RT. Fixed
samples were centrifuged at 125× g for 5 min in a cytospin centrifuge onto gold-sputtered and
Poly-L-Lysin-coated coverslips as described above. After incubation with glycine (0.05 M) combined
with 0.1% bovine serum albumin (BSA, blocking agent, Merck, Darmstadt, Germany) in PBS for
15 min at RT, platelets were washed with PBS/BSA. Afterwards platelets were incubated with a
1st anti-β-toxin antibody (10A2, 1:10) over night at 4 ◦C and a 2nd colloidal gold-labeled antibody
(18 nm, goat anti mouse igG antibody, Jackson ImmunoResearch, West Grove, PA, USA) for 90 min
at RT. Postfixation was done with 2% OsO4 (Polysciences, Warrington, PA, USA) in 0.1 M cacodylate
buffer for 30 min. After two washes in 0.1 M cacodylate buffer, the samples were dehydrated through
an ascending ethanol series and dried by evaporation of hexamethyldisilazane as described above.
4.5. Detection of Toxin Oligomerization by Western Blot Analyses
Porcine and human platelets (3.2 × 109/mL) were incubated with rCPB (1 µg/mL) for 0, 5, 30
and 60 min, followed by washing with PBS (centrifugation at 700× g for 10 min at 4 ◦C), to remove
unbound rCPB. After lysis in 100 µL RIPA-buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% NP-40,
0.25% Na-deoxycholate, 1 mM EDTA and 0.1% SDS), lysates were centrifuged (15,294× g, 10 min,
4 ◦C). After boiling in SDS sample buffer (Laemmli buffer), equal amounts of proteins were separated
by a 7% SDS gel and blotted on a nitrocellulose membrane (Trans-Blot Turbo Transfer Pack, Bio-Rad,
Hercules, CA, USA). Western blots were developed using the mouse anti-CPB monoclonal antibody
10A2 (1:1.000) and a donkey anti-mouse secondary antibody IRDye 680 CW (1:6.000 dilution, Li-Cor
Biosciences). As a loading control, identical volumes of samples were separated by 7% SDS-PAGE,
blotted on nitrocellulose membranes and developed using anti-actin antibodies (1:5.000 dilution,
anti-β-actin antibody, Sigma) followed by a donkey anti-mouse secondary antibody IRDye 680 CW
(1:6.000 dilution). Signals were detected and visualized using the Azure c600 imaging system
(Azure Biosystems, Inc., Dublin, CA, USA).
4.6. Functional Assay
Platelet function was evaluated with the platelet function assay (Siemens Healthcare Diagnostics
Products GmbH, Marburg, Germany), based on previous publications [28,29]. Shortly, this tests
the process of platelet adhesion and aggregation following a simulated vascular injury in vitro.
Citrated whole blood is aspirated from the sample reservoir through a collagen- and ADP-coated
capillary with a small aperture, which exposes platelets to shear stress and two activating factors.
During the test, functional platelets adhere to the membrane, become activated form aggregates to
build a thrombus at the aperture, thereby gradually reducing the blood flow. The platelet function
analyzer system determines the time from the start of the test until the platelet plug occludes the
aperture, and reports this time interval as the closure time [30]. The physiological values for samples
from healthy human blood donors ranges between 65 and 130 s. Citrated whole blood (3.8 mL) was
provided by volunteer employees of the authors’ institute. All subjects gave their informed consent
for inclusion of anonymized biological material derived from their blood samples in research studies
and the study was conducted in accordance with the Declaration of Helsinki. Blood samples were
incubated with rCPB (1 µg/mL) at RT for 15, 30 and 60 min. Control samples were left untreated or
incubated either with neutralized rCPB or the 10A2 antibody only. For each condition, 10 samples were
measured. Statistics were done using the NCSS software. At 60 min, often no closure was achieved
within the measurement interval of the test system, but for statistic calculations, the value was set
at 300 s, the maximum value of the test system. Differences between the treated groups were tested
by means of analysis of variance (ANOVA) with Bonferroni (All-Pairwise) multiple-comparison test
(the level of significance, alpha, was set to alpha 0.05).
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